Report topline data from the Phase 2 HONOR trial of ARD-101
Deadline not yet reached (65 days left)
- Announced
- 13 Aug 2025
- Due
- 31 Dec 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“anticipated topline data readout in the second half of 2026.”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -92 days
- 2 versions
-
Version 1 · original · stated 13 Aug 2025
Deadline 31 Dec 2026 (“in the second half of 2026”) · wording expected
-
Version 2 · stated 12 Feb 2026
Deadline 30 Sep 2026 (“in the third quarter of 2026”) · wording expected
“The opportunity to help advance the company’s lead asset, ARD-101, with topline Phase 3 data expected in the third quarter of 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 2 HONOR trial topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Aardvark Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-AARD-002616 · Corrections policy